Glaukos (GKOS) Expected to Post Quarterly Earnings on Wednesday

Posted by on Jul 22nd, 2026

Glaukos (NYSE:GKOS – Get Free Report) is anticipated to release its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Glaukos to announce earnings of ($0.2229) per share and revenue of $150.9940 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. During the same quarter last year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was up 41.2% on a year-over-year basis. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Trading Down 1.4%

Shares of NYSE:GKOS opened at $153.33 on Wednesday. The company has a market capitalization of $9.01 billion, a PE ratio of -46.75 and a beta of 0.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. Glaukos has a 12-month low of $73.16 and a 12-month high of $161.53. The business’s fifty day simple moving average is $135.13 and its 200-day simple moving average is $122.66.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 19,573 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the transaction, the chief operating officer owned 73,419 shares in the company, valued at approximately $10,538,563.26. This represents a 21.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $155.00, for a total transaction of $1,550,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,681 shares of the company’s stock, valued at approximately $6,770,555. This represents a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,273 shares of company stock worth $8,882,003 in the last quarter. 5.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new position in Glaukos in the 4th quarter worth $28,000. Smartleaf Asset Management LLC grew its stake in Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Glaukos during the 4th quarter valued at about $128,000. Van ECK Associates Corp increased its holdings in shares of Glaukos by 24.2% in the third quarter. Van ECK Associates Corp now owns 1,738 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 339 shares during the period. Finally, Focus Partners Wealth increased its holdings in shares of Glaukos by 6.9% in the third quarter. Focus Partners Wealth now owns 2,714 shares of the medical instruments supplier’s stock valued at $202,000 after purchasing an additional 176 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company raised their price objective on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Stifel Nicolaus boosted their target price on shares of Glaukos from $170.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Wall Street Zen lowered shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday. Truist Financial raised their price target on shares of Glaukos from $160.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $164.00 price objective on shares of Glaukos in a research report on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $154.85.

Read Our Latest Analysis on Glaukos

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Featured Articles

Earnings History for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.